142 related articles for article (PubMed ID: 22042943)
1. Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma.
Honda K; Saraya T; Tamura M; Yokoyama T; Fujiwara M; Goto H
J Clin Oncol; 2011 Dec; 29(35):e859-60. PubMed ID: 22042943
[No Abstract] [Full Text] [Related]
2. Bronchoesophageal fistula and fatal hemoptysis after bevacizumab-containing chemotherapy without radiation in lung cancer.
Schreiber J; Waldburg N
J Clin Oncol; 2012 Nov; 30(32):e324. PubMed ID: 23008311
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
4. Transient acantholytic dermatosis in a patient with prostate cancer.
Khan MS; Khan M; Aivaz O
Dermatol Online J; 2020 Feb; 26(2):. PubMed ID: 32239889
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.
Tao H; Meng Q; Li M; Shi L; Tang J; Liu Z
Thorac Cancer; 2018 Feb; 9(2):298-304. PubMed ID: 29297985
[TBL] [Abstract][Full Text] [Related]
6. Periaortitis associated with anti-neutrophil cytoplasmic antibodies induced by bevacizumab combination therapy.
Murakami S; Saito H; Ohe M; Kondo T; Oshita F; Yamada K
Intern Med; 2013; 52(5):589-91. PubMed ID: 23448770
[TBL] [Abstract][Full Text] [Related]
7. [A case of advanced lung adenocarcinoma with cavity formation shrunken by bevacizumab added on the 3rd course of 6th-line chemotherapy].
Miyazaki M; Naoki K; Sato T; Tanaka K; Tsuzuki K; Yoshida S; Tomomatsu K; Tasaka S; Soejima K; Sayama K; Asano K
Gan To Kagaku Ryoho; 2012 Mar; 39(3):421-4. PubMed ID: 22421771
[TBL] [Abstract][Full Text] [Related]
8. Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors.
Miyazaki K; Satoh H; Tamura T
Lung Cancer; 2016 Dec; 102():135. PubMed ID: 27526980
[No Abstract] [Full Text] [Related]
9. Computed tomography perfusion: a new method to evaluate response to therapy in lung cancer.
Fraioli F; Vetere S; Anile M; Venuta F
J Thorac Oncol; 2011 Sep; 6(9):1599-600. PubMed ID: 21849856
[No Abstract] [Full Text] [Related]
10. Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer.
Hentrich M; Schiel X; Scheidt B; Reitmeier M; Hoffmann U; Lutz L
Acta Oncol; 2008; 47(1):155-6. PubMed ID: 18097781
[No Abstract] [Full Text] [Related]
11. Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
Ou W; Li N; Wang SY; Li J; Liu QW; Huang QA; Wang BX
Cancer; 2016 Mar; 122(5):740-7. PubMed ID: 26700505
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
13. [A case of intractable pneumothorax in a patient with pulmonary adenocarcinoma during bevacizumab-containing chemotherapy].
Tamura T; Tamura S; Nasu H; Fujimoto T; Kinoshita T
Nihon Kokyuki Gakkai Zasshi; 2011 Sep; 49(9):702-6. PubMed ID: 22073619
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
16. MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials.
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):4-6. PubMed ID: 24852395
[No Abstract] [Full Text] [Related]
17. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
[TBL] [Abstract][Full Text] [Related]
18. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer.
Hainsworth JD; Fang L; Huang JE; Karlin D; Russell K; Faoro L; Azzoli C
J Thorac Oncol; 2011 Jan; 6(1):109-14. PubMed ID: 21107290
[TBL] [Abstract][Full Text] [Related]
19. [An intra-thyroid metastasis revealing non-small cell lung cancer].
Boukir A; El Kabous M; Azghari I; Boutayeb S; El Ghissassi I; Mrabti H; Errrihani H
Pan Afr Med J; 2015; 22():189. PubMed ID: 26918084
[TBL] [Abstract][Full Text] [Related]
20. [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin
in Patients with IIIa Lung Adenocarcinoma].
Zhang S; Xu P; Yuan C; Ou W
Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):365-8. PubMed ID: 26104893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
